Search

Search Constraints

You searched for: Author/Creator Kii, Takayuki

Search Results

1. 330. RANDOMIZED PHASE II STUDY OF DOCETAXEL VERSUS PACLITAXEL IN PATIENTS WITH ESOPHAGEAL SCC REFRACTORY TO FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY: OGSG1201. (24th September 2022)

2. Fluoropyrimidine-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea. (1st February 2019)

3. Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003). Issue 1 (28th November 2020)

4. Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003). Issue 1 (28th November 2020)

5. Phase I/II trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Issue 9 (September 2014)

6. Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). (3rd August 2020)

7. PS02.162: THREE-YEAR OVERALL SURVIVAL UPDATE FROM PHASE II STUDY OF CHEMOSELECTION WITH DCF AND SUBSEQUENT CONVERSION SURGERY FOR LOCALLY ADVANCED UNRESECTABLE ESOPHAGEAL CANCER. (14th September 2018)

8. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. (September 2021)